Project Grant R01HL173972
Award Date
7/1/24
Completion Date
5/31/28
Dollars Obligated
$2.2M
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Shreveport, LA 71130, USA
Similar Awards
The federal Project Grant award in the amount of $2,070,048.00 was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research (CFDA 93.837) program. The award supports a comprehensive investigation of the cellular and molecular mechanisms regulating atherosclerotic plaque stability and instability, with the goal of identifying novel therapeutic targets to reduce cardiovascular disease risk. The research program, led by The Trustees of Columbia...
This $381,250 federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) aims to investigate the atheroprotective impact of the ABC-transporters ABCA1 and ABCG1 in vascular smooth muscle cells. The research seeks to determine whether increasing the expression of these cholesterol efflux transporters in vascular smooth muscle cells can protect against the progression of atherosclerosis, a leading cause of...
This federal Project Grant award R01HL172809, provided by the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research), supports a research project focused on understanding the role of vascular smooth muscle cells (VSMCs) and the lymphatic network in the development of atherosclerosis. The $559,893 award, which runs from January 6, 2025 to November 30, 2029, will fund three main research aims: Determining the functional role of VSMC-derived R-spondin 2 (RSPO2)...
The National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), has awarded a $700,398 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The Trustees of Columbia University in the City of New York. This grant, awarded on July 1, 2024, with a final completion date of May 31, 2028, will support research to integrate spatial transcriptomics, genetics, and histomorphology to study causal mechanisms of atherosclerotic...
This federal Project Grant award, with ID R01HL179083, was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research federal grant program (CFDA 93.837). The $705,405 award supports research to characterize the role of adventitial fibroblasts, an understudied cell population, in the formation and calcification of atherosclerotic plaque. Key objectives include determining the mechanisms by which genetic ablation of adventitial fibroblasts reduces...
The federal Project Grant award R01HL176322, provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research Program (CFDA 93.837), supports research to define lipoprotein(a) (Lp(a)) risk thresholds, explore mechanisms for Lp(a)-associated heightened atherosclerotic cardiovascular disease (ASCVD) risk, and study regulation of hepatic Lp(a) production in people with HIV (PWH). The $1,485,606 award, with a performance period from Sep 1, 2024 to Aug...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $2,508,741 to investigate the functional interactions between lipoproteins and protease inhibitors in atherosclerosis. The research aims to: 1) examine the structural and functional interactions between lipoproteins, such as LDL and HDL, and the protease inhibitor alpha-1-antitrypsin (AAT); 2) determine the role of...
This federal Project Grant award for $2,395,029.00 from the National Heart Lung and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research on the role of endothelial cell metabolism and cell cycle regulation in mediating the effects of fluid shear stress on vascular health and atherosclerosis risk. The research aims to conduct a thorough unbiased analysis of the differential effects of laminar versus disturbed blood flow on endothelial cell...
This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) to Saint Louis University will support research to investigate the role of age, sex, and hormonal status in the development of atherosclerotic cardiovascular disease (CVD). The $416,625 award, spanning August 1, 2024 to July 31, 2026, will test the hypothesis that promoting an anti-inflammatory, pro-resolving environment in atherosclerotic plaques can be atheroprotective. The research will...
This federal Project Grant award for $737,111, provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), supports research to investigate the role of low-density lipoprotein (LDL) in hemostasis and hemophilia A. The key objectives are to: 1) test if LDL associates with coagulation factors VIII and von Willebrand factor, and improves hemostasis; 2) examine if LDL extends the half-life of factor VIII through slower...